Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Boehringer Ingelheim
Harvard Business School
Medtronic
Chinese Patent Office
Citi
Farmers Insurance
Cantor Fitzgerald

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,173,172

« Back to Dashboard

Which drugs does patent 8,173,172 protect, and when does it expire?

Patent 8,173,172 protects ASMANEX TWISTHALER and is included in one NDA.

Protection for ASMANEX TWISTHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 8,173,172
Title:Preparation of powder agglomerates
Abstract: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
Inventor(s): Yang; Tsong-Toh (Warren, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:11/947,608
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 8,173,172

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,173,172

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,387,794 Preparation of powder agglomerate ➤ Sign Up
7,687,073 Preparation of powder agglomerates ➤ Sign Up
6,495,167 Preparation of powder agglomerates ➤ Sign Up
6,503,537 Preparation of powder agglomerates ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
UBS
Argus Health
Farmers Insurance
Mallinckrodt
Dow
Chinese Patent Office
Medtronic
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.